X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dishman Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs TEVA PHARMA (Israel) - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
TEVA PHARMA
Dec-13
DISHMAN PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs3742,860-   
Low Rs1292,484-   
Sales per share (Unadj.) Rs197.81,641.2-  
Earnings per share (Unadj.) Rs21.2102.5-  
Cash flow per share (Unadj.) Rs34.7235.2-  
Dividends per share (Unadj.) Rs2.0089.75-  
Dividend yield (eoy) %0.83.4 23.7%  
Book value per share (Unadj.) Rs179.91,823.0-  
Shares outstanding (eoy) m80.69848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.6 78.1%   
Avg P/E ratio x11.926.1 45.5%  
P/CF ratio (eoy) x7.211.4 63.8%  
Price / Book Value ratio x1.41.5 95.4%  
Dividend payout %9.487.5 10.8%   
Avg Mkt Cap Rs m20,3062,265,763 0.9%   
No. of employees `0000.844.9 1.8%   
Total wages/salary Rs m5,3550-   
Avg. sales/employee Rs Th19,252.730,964.8 62.2%   
Avg. wages/employee Rs Th6,459.50-   
Avg. net profit/employee Rs Th2,064.11,934.3 106.7%   
INCOME DATA
Net Sales Rs m15,9611,391,712 1.1%  
Other income Rs m2650-   
Total revenues Rs m16,2261,391,712 1.2%   
Gross profit Rs m4,103381,121 1.1%  
Depreciation Rs m1,091112,493 1.0%   
Interest Rs m94427,335 3.5%   
Profit before tax Rs m2,334241,292 1.0%   
Minority Interest Rs m01,096 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-158,395 0.0%   
Tax Rs m624-2,946 -21.2%   
Profit after tax Rs m1,71186,939 2.0%  
Gross profit margin %25.727.4 93.9%  
Effective tax rate %26.7-1.2 -2,188.8%   
Net profit margin %10.76.2 171.6%  
BALANCE SHEET DATA
Current assets Rs m11,018939,957 1.2%   
Current liabilities Rs m9,517819,722 1.2%   
Net working cap to sales %9.48.6 108.8%  
Current ratio x1.21.1 101.0%  
Inventory Days Days11091 121.7%  
Debtors Days Days3596 36.3%  
Net fixed assets Rs m16,304454,564 3.6%   
Share capital Rs m1613,426 4.7%   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,5161,545,928 0.9%   
Long term debt Rs m4,189711,613 0.6%   
Total assets Rs m29,8053,180,508 0.9%  
Interest coverage x3.59.8 35.3%   
Debt to equity ratio x0.30.5 62.7%  
Sales to assets ratio x0.50.4 122.4%   
Return on assets %8.93.6 248.0%  
Return on equity %11.85.6 209.6%  
Return on capital %17.54.9 355.5%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,786221,767 1.3%  
From Investments Rs m-1,529-78,581 1.9%  
From Financial Activity Rs m-941-266,024 0.4%  
Net Cashflow Rs m316-122,838 -0.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 68.51 Rs / USD

Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare DISHMAN PHARMA With: ELDER PHARMA  ALEMBIC LTD  UNICHEM LAB  CADILA HEALTHCARE  GSK PHARMA  



Today's Market

Sensex Ends 218 Points Lower; Tata Steel & Tata Motors Top Losers(Closing)

Indian share markets ended lower in the final hour of the trade. At the closing bell, the BSE Sensex finished lower by 218 points and the NSE Nifty finished down by 82 points.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Has A Bank Ever Told You Its Deposits are Riskier than Stocks? These Should Have...(The 5 Minute Wrapup)

Jul 3, 2018

Left on their own, the banks would possibly have to mark down the value of deposits by 90% to 100%.

The Real Truth About India's FDI, Beyond WhatsApp(Vivek Kaul's Diary)

Jul 4, 2018

The FDI numbers do not look very impressive once we adjust for repatriations as well as the overall growth in the economy.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS